Merck cutting 8,500 jobs in massive R&D, commercial shakeup
This article was originally published in Scrip
Merck & Co. is cutting 8,500 jobs and jettisoning some research and development programs as the big drug maker refocuses its strategy and moves to save $2.5 billion a year in annual costs.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.